Wed, Apr 23, 2014, 4:31 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • staz012 staz012 Sep 22, 2013 1:52 PM Flag

    Big news coming part 2

    Could this be that ???

    INCB39110 – a JAK1 Inhibitor

    Three proof-of-concept studies evaluating INCB39110 in patients with myelofibrosis, psoriasis and rheumatoid arthritis are underway, with preliminary results expected in the second half of 2013. The results of these studies are expected to inform us as to the most appropriate indications for further development.
    Source: press release, 5/02/13.


    A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis
    Estimated Enrollment: 95
    Study Start Date: March 2012
    Estimated Study Completion Date: September 2013
    Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
    Source: clinical

    Compound/Device Specialty Indication Compound Class Target
    INCB-039110 Rheumatology Rheumatoid Arthritis (RA) Janus-associated Kinase Inhibitors Janus-associated Kinase
    Mechanism of action: INCB-039110, a SM-inhibitor, reduces cell proliferation by disrupting the signaling of the Janus-associated kinases (JAK) pathway. Aberrant activation of the JAK-STAT pathway has been documented in a variety of autoimmune diseases and cancers.

    Phase of Development: II

    Event Type: Data: Phase II trial results

    Dates: 2013-10-25 - 2013-10-30 L

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
46.96-2.36(-4.79%)4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.